M Emmy M Dolman
Overview
Explore the profile of M Emmy M Dolman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
784
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
3.
Mayoh C, Mao J, Xie J, Tax G, Chow S, Cadiz R, et al.
Cancer Res
. 2023 Jul;
83(16):2716-2732.
PMID: 37523146
Significance: Integrating HTS with molecular profiling is a powerful tool for expanding precision medicine to support drug treatment recommendations and broaden the therapeutic options available to high-risk pediatric cancers.
4.
Keller K, Koetsier J, Schild L, Amo-Addae V, Eising S, van den Handel K, et al.
BMC Cancer
. 2023 Apr;
23(1):310.
PMID: 37020198
Background: Pediatric cancer is the leading cause of disease-related death in children and the need for better therapeutic options remains urgent. Due to the limited number of patients, target and...
5.
Eleveld T, Vernooij L, Schild L, Koopmans B, Alles L, Ebus M, et al.
Front Oncol
. 2023 Mar;
13:1130034.
PMID: 36895472
Introduction: Mutations affecting the RAS-MAPK pathway occur frequently in relapsed neuroblastoma tumors and are associated with response to MEK inhibition . However, these inhibitors alone do not lead to tumor...
6.
Keller K, Eleveld T, Schild L, van den Handel K, van den Boogaard M, Amo-Addae V, et al.
Front Oncol
. 2022 Oct;
12:929123.
PMID: 36237330
Neuroblastoma is the most common extracranial solid tumor found in children and despite intense multi-modal therapeutic approaches, low overall survival rates of high-risk patients persist. Tumors with heterozygous loss of...
7.
Meister M, Groot Koerkamp M, de Souza T, Breunis W, Frazer-Mendelewska E, Brok M, et al.
EMBO Mol Med
. 2022 Aug;
14(10):e16001.
PMID: 35916583
Rhabdomyosarcomas (RMS) are mesenchyme-derived tumors and the most common childhood soft tissue sarcomas. Treatment is intense, with a nevertheless poor prognosis for high-risk patients. Discovery of new therapies would benefit...
8.
Schneider P, Castro P, Pinhancos S, Kerstjens M, van Roon E, Essing A, et al.
EJHaem
. 2022 Jul;
1(2):527-536.
PMID: 35844991
-rearranged acute lymphoblastic leukemia (ALL) represents a highly aggressive ALL subtype, characterized by aberrant DNA methylation patterns. DNA methyltransferase inhibitors, such as decitabine have previously been demonstrated to be effective...
9.
Wander P, Arentsen-Peters S, Vrenken K, Pinhanos S, Koopmans B, Dolman M, et al.
Biomedicines
. 2022 Mar;
10(3).
PMID: 35327440
KMT2A-rearranged acute lymphoblastic leukemia (ALL) in infants (<1 year of age) represents an aggressive type of childhood leukemia characterized by a poor clinical outcome with a survival chance of <50%....
10.
Keller K, Krausert S, Gopisetty A, Luedtke D, Koster J, Schubert N, et al.
Eur J Cancer
. 2021 Dec;
162:107-117.
PMID: 34963094
Background: Owing to the high numbers of paediatric cancer-related deaths, advances in therapeutic options for childhood cancer is a heavily studied field, especially over the past decade. Classical chemotherapy offers...